201 completed, 35 terminated, 24 recruiting, 16 active not recruiting. 303 Phase 2, 36 Phase 1, 10 Phase 3.
Follow Atopic Dermatitis: new trials by email Literature Review of Atopic Dermatitis trials Research Report on Atopic Dermatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis Ivermectin Pill - Atopic Dermatitis | Phase 2 | Withdrawn | Stanford University | 2030-12-01 | 2024-12-02 | |
| Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis EC-18, Placebo EC-18 - Atopic Dermatitis | Phase 2 | Not yet recruiting | Enzychem Lifesciences Corporation | 150 | 2027-05-01 | 2026-08-28 |
| A Study Evaluating TRIV-573 in Atopic Dermatitis TRIV-573, Placebo - Atopic Dermatitis | Phase 2 | Recruiting | Triveni Bio | 90 | 2026-09-09 | 2026-10-28 |
| A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis ENV-294, Placebo - Atopic Dermatitis | Phase 2 | Recruiting | Enveda Therapeutics | 200 | 2026-06-29 | 2026-08-06 |
| Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis IMG-007 - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Enrolling by invitation | Inmagene LLC | 400 | 2026-06-05 | 2026-07-29 |
| A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis VC005 group, VC005 Placebo group - Atopic Dermatitis | Phase 2 | Recruiting | Jiangsu vcare pharmaceutical technology co., LTD | 120 | 2026-06-01 | 2026-07-07 |
| A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis Camoteskimab, Placebo - Atopic Dermatitis, Atopic | Phase 2 | Recruiting | Apollo Therapeutics Ltd | 280 | 2026-05-28 | 2026-08-28 |
| HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis HL-300, Placebo - Atopic Dermatitis | Phase 1 / Phase 2 | Recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 156 | 2026-05-26 | 2026-06-23 |
| A Clinical Study to Evaluate SM17 for Atopic Dermatitis SM17 for subcutaneous injection, SM17 placebo for subcutaneous injection - Atopic Dermatitis | Phase 2 | Recruiting | SinoMab BioScience Ltd | 200 | 2026-03-31 | 2026-04-06 |
| A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis IBI3002, Placebo, Dupilumab - Atopic Dermatitis | Phase 2 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 120 | 2026-02-06 | 2026-02-13 |
| A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis The high-dose group of ZL-82 tablets, The low-dose group of ZL-82 tablets, The placebo group - Atopic Dermatitis | Phase 2 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 111 | 2026-02-03 | 2026-02-04 |
| Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD Soquelitinib, Placebo - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Recruiting | Corvus Pharmaceuticals, Inc. | 200 | 2026-02-01 | 2026-03-05 |
| Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome Abrocitinib - Atopic Dermatitis, Alopecia Areata | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 56 | 2026-01-12 | 2026-10-16 |
| A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis Afimkibart - Atopic Dermatitis | Phase 2 | Active not recruiting | Hoffmann-La Roche | 120 | 2026-01-08 | 2026-10-26 |
| A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis Dupilumab, Placebo, IBI356 - Atopic Dermatitis | Phase 2 | Terminated | Innovent Biologics (Suzhou) Co. Ltd. | 18 | 2025-12-31 | 2026-10-27 |
| A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis Galvokimig, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | UCB Biopharma SRL | 165 | 2025-12-29 | 2026-09-25 |
| A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis KT-621, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Kymera Therapeutics, Inc. | 200 | 2025-11-24 | 2026-10-06 |
| Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study Oral roflumilast - Atopic Dermatitis | Phase 2 | Recruiting | Nora Mohamed Abdelrazik | 36 | 2025-11-20 | 2025-12-30 |
| A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema PF-08049820, Placebo - Atopic Dermatitis, Eczema, Atopic | Phase 2 | Recruiting | Pfizer | 165 | 2025-11-20 | 2026-11-05 |
| Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis GIA632, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 34 | 2025-11-10 | 2026-05-14 |
Showing 20 of 303. Sign in to see all of them.
Dermatitis, Atopic (303) · Eczema (76) · Dermatitis (23) · Pruritus (22) · Skin Diseases (17) · Immune System Diseases (6) · Skin Diseases, Eczematous (5) · Lymphoma, Follicular (4) · Psoriasis (3) · Food Hypersensitivity (2) · Inflammation (2) · Skin Diseases, Genetic (2) · Staphylococcal Infections (2) · Acne Vulgaris (1) · Alopecia (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (303) · Genetic Diseases, Inborn (303) · Skin and Connective Tissue Diseases (303) · Hypersensitivity (302) · Hypersensitivity, Immediate (302) · Skin Diseases, Genetic (301) · Skin Diseases, Eczematous (298) · Immune System Diseases (297) · Skin Diseases (286) · Dermatitis (280) · Pathological Conditions, Signs and Symptoms (26) · Signs and Symptoms (23) · Skin Manifestations (23) · Hemic and Lymphatic Diseases (5) · Immunoproliferative Disorders (5)
dupilumab (9) · Ointments (5) · R-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-4-methyl-2-(((2-methyl-5-quinolyl)amino)methyl)pentan-2-ol (5) · difamilast (4) · methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)amino)carbonyl)benzoate (4) · nemolizumab (4) · Exercise (3) · Triamcinolone (3) · abrocitinib (3) · apremilast (3) · lebrikizumab (3) · tralokinumab (3) · 8,11,14-Eicosatrienoic Acid (2) · Cholecalciferol (2) · Cyclosporine (2)
Pfizer (9) · LEO Pharma (8) · Regeneron Pharmaceuticals (8) · Bayer (7) · Novartis Pharmaceuticals (7) · Keymed Biosciences Co.Ltd (6) · Aclaris Therapeutics, Inc. (5) · DS Biopharma (5) · Galderma R&D (5) · Akeso (4) · Eli Lilly and Company (4) · Hoffmann-La Roche (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Organon and Co (4) · AbbVie (3)
United States (170) · Canada (75) · Germany (66) · Poland (53) · China (35) · Japan (32) · Australia (31) · United Kingdom (29) · Czechia (28) · Hungary (25) · Spain (21) · France (19) · South Korea (17) · Taiwan (16) · Bulgaria (15)
David Zammit, Ph.D. (2) · Emma Guttman, MD, PhD (2) · Eric Simpson, MD (2)
PMID 25006719, PMID 39077906, PMID 16895558, PMID 18595980, PMID 18645136, PMID 20970174, PMID 21039597, PMID 21771098, PMID 21771118, PMID 22093109, PMID 22508772, PMID 23638978, PMID 24279519, PMID 24284985, PMID 24331381, PMID 26439129, PMID 26454361, PMID 26569624, PMID 26581111, PMID 26618557, PMID 26777100, PMID 27268421, PMID 28249150, PMID 28845523, PMID 29753033, PMID 29906525, PMID 30326954, PMID 30472801, PMID 30738171, PMID 30909923, PMID 31449914, PMID 31577341, PMID 31595499, PMID 31629805, PMID 31786154, PMID 31838180, PMID 32101256, PMID 32315497, PMID 33165005, PMID 33333295, PMID 33795561, PMID 33826132, PMID 33954933, PMID 33982267, PMID 34374027, PMID 34406619, PMID 34857814, PMID 35061234, PMID 35088348, PMID 35342978
2018 (8), 2025 (5), 2014 (3), 2015 (2), 2016 (2), 2023 (2), 2008 (1), 2017 (1), 2019 (1), R61AR084210 (1), U01AI147462 (1)